Activated abl oncogenes and apoptosis: Differing responses of transformed myeloid progenitor cell lines

Blood

Volumn 87, Issue 10, 1996, Pages 4368-4375

  Zhu, Jiangyu ^a   Nabissa, Pappathi M ^a   Hoffman, Barbara ^a   Liebermann, Dan A ^a   Shore, Scott K ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYL SULFOXIDE;

ABELSON MURINE LEUKEMIA ONCOVIRUS; ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL LINE; CELL TRANSFORMATION; ENZYME ACTIVITY; GENE ACTIVATION; GENE EXPRESSION; MOUSE; MYRISTYLATION; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTO ONCOGENE; RECEPTOR UPREGULATION; STEM CELL;

EID: 0029880874     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.10.4368.bloodjournal87104368     Document Type: Article

References (37)

1. Konopka J, Witte ON: Detection of tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol Cell Biol 5:3116, 1985
2. Shore SK, Reddy EP: The Abelson leukemia viral oncogene, in Deisseroth AB, Arlinghaus RB (eds): Chronic Myelogenous Leukemia Molecular Approaches to Research and Therapy. New York, NY, Marcel Dekker, 1991, p 153
3. Kuzrock R, Gutterman JU, Talpaz M: The molecular genetics of Philadelphia chromosome positive leukemias. New Engl J Med 319:990, 1988
4. Etten RA, Jackson P, Baltimore D: The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 58:669, 1989
5. McWhirter J, Wang JYJ: Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/ abl fusion proteins. Mol Cell Biol 11:1553, 1991
6. Sawyers CL, McLaughlin J, Goga A, Havlik M, Witte O: The nuclear tyrosine kinase c-Abl negatively regulates cell growth. Cell 77:121, 1994
7. Kelliher MA, McLaughlin AJ, Witte ON, Rosenberg N: Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA 87:6649, 1990
8. Cook WD, Frazekas de St. Groth B, Miller JFAP, McDonald HR, Gabathuler R: Abelson virus transformation of an interleukin 2-dependant antigen-specific T cell line. Mol Cell Biol 7:2631, 1987
9. Rovera G, Valtieri M, Mavilio F, Reddy EP: Effect of Abelson murine leukemia virus on granulocyte differentiation and IL-3 dependence of a murine progenitor cell line. Oncogene 1:29, 1987
10. Laneuville P, Heisterkamp N, Groffen J: Expression of the chronic myelogenous leukemia-associated p210bcr/abl oncoprotein in a murine IL-3 dependant myeloid cell line. Oncogene 6:275, 1991
11. Daley GQ, Van Etten RA, Jackson PK, Bernards A, Baltimore D: Non-myristoylated Abl proteins transform a factor-dependant hematopoietic cell line. Mol Cell Biol 12:1864, 1992
12. Valtieri M, Tweardy DJ, Caracciolo D, Johnson K, Mavilio F, Altmann S, Santoli, D, Rovera G: Cytokine-dependant granulocytic differentiation: Regulation of proliferative and differentiative responses in a murine progenitor cell line. J Immunol 138:3829, 1987
13. Daley GQ, McLaughlin J, Witte ON, Baltimore D: The CML-specific p210 bcr/abl protein, unlike v-abl does not transform NIH/ 3T3 cells. Science 237:824, 1987
14. Shore SK, LaCava M, Yendapalli S, Reddy EP: Structural alterations in the carboxyl-terminal domain of the BCRABL gene product activate its fibroblastic transforming potential. J Biol Chem 269:5413, 1994
15. Sefton BM, Trowbridge IS, Cooper J: The transforming proteins of Rous sarcoma virus, Harvey sarcoma virus and Abelson virus contain tightly bound lipid. Cell 31:465, 1982
16. McWhiter JR, Wang JYJ: An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J 12:1533, 1993
17. Greenberger JS, Sakakeeny MA, Humphries RK, Eaves CJ, Eckner RJ: Demonstration of permanent factor-dependant multipotential (erythroid/neutrophil/basophil) hematopoietic progenitor cell lines. Proc Natl Acad Sci USA 80:2931, 1983
18. Korsmeyer SJ: Bcl-2 initiates a new catagory of oncogenes: Regulators of cell death. Blood 80:879, 1992
19. Oltivai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609, 1993
20. Lee JC, Hapel AJ, Ihle J: Constitutive production of a unique lymphokine (IL-3) by the WEHI-3-cell line. J Immunol 128:2393, 1982
21. Kirschmeier PT, Housey GM, Johnson MD, Perkins AS, Weinstein IB: Construction and characterization of a retroviral vector demonstrating efficient expression of cloned DNA sequences. DNA 7:219, 1988
22. Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC: Terminal differentiation of human promyelocytic leukemia cells by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci USA 75:2458, 1979
23. Keller JR, Ruscetti SK, Ruscetti FW: Introduction of v-abl oncogene induces monocytic differentiation of an IL-3 dependent myeloid progenitor cell line. Oncogene 5:549, 1990
24. Wyllie AH, Kerr JFR, Currie AR: Cell death: The significance of apoptosis. Int Rev Cytol 68:251, 1980
25. Selvakumaran M, Lin HK, Miyashita T, Wang HG, Krajewski S, Reed JC, Hoffman B, Liebermann D: Immediate up-regulation of bax expression by p53 but not TGFβ1: A paradigm for distinct apoptotic pathways. Oncogene 9:1791, 1994
26. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1, 1994
27. Nuñez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ: Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 144:3602, 1990
28. Williams GT, Smith CA, Spooncer E, Dexler TM, Taylor DR: Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 343:76, 1990
29. Collins MKL, Marvel J, Malde P, Lopez-Rivas A: Interleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents. J Exp Med 176:1043, 1992
30. Laneuville P, Timm M, Hudson AT: bcr/abl expression in 32Dc13(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors. Cancer Res 54:1360, 1994
31. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG: BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83:1179, 1994
32. Garcia IS, Grütz G: Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCLZ. Proc Natl Acad Sci USA 92:5287, 1995
33. Delia D, Aiello A, Soligo D, Fontanella E, Melani C, Pezella F, Pierotti MA, Della Porta G: bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells Blood 79:1291, 1992
34. Evans CA, Owen-Lynch PJ, Whetton AD, Dive C: Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hematopoetic cells. Cancer Res 53:1735, 1993
35. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J, Gishizky ML: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the Grb-2 adaptor protein. Cell 75:175, 1993
36. Puli L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, Arlinghaus RB, Pawson T: Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 13:764, 1994
37. Reuther GW, Haian F, Cripe LD, Collier RJ, Pendergast AM: Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family. Science 266:129, 1994